Short Term Rating on Qiagen N.V. (QGEN)

Qiagen N.V. (QGEN) has an average broker rating of 2.75, which is interpreted as a Hold, as rated by 12 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 9 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 4, which is also a Sell. 1 considers that the stock is a Sell.

Qiagen N.V. (QGEN) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $27 and the lowest price target forecast is $22. The average forecast of all the analysts is $24.25 and the expected standard deviation is $1.83.

Company shares have received an average consensus rating of Hold for the current week


Qiagen N.V. (NASDAQ:QGEN): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $22.31 and $22.07 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $22.32. The buying momentum continued till the end and the stock did not give up its gains. It closed at $22.15, notching a gain of 0.50% for the day. The total traded volume was 1,427,574 . The stock had closed at $22.04 on the previous day.

QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Companys bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.